The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Rousselet, E., Marcinkiewicz, J., Kriz, J., Zhou, A., Hatten, M. E., Prat, A., & Seidah, N. G. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m014118 · Cited by 107
Cited by
Inflammation and atherosclerosis: signaling pathways and therapeutic intervention
Kong, P., Cui, Z.-Y., Huang, X.-F., Zhang, D.-D., Guo, R.-J., & Han, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00955-7 · Cited by 1,183
New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway
Tang, Z.-H., Peng, J., Ren, Z., Yang, J., Li, T.-T., Li, T.-H., Wang, Z., Wei, D.-H., Liu, L.-S., Zheng, X.-L., et al. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.04.023 · Cited by 291
PCSK9 and inflammation: a review of experimental and clinical evidence
Momtazi-Borojeni, A. A., Sabouri-Rad, S., Gotto, A. M., Pirro, M., Banach, M., Awan, Z., Barreto, G. E., & Sahebkar, A. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz022 · Cited by 188
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): From bench to bedside
Bao, X., Liang, Y., Chang, H., Cai, T., Feng, B., Gordon, K., Zhu, Y., Shi, H., He, Y., & Xie, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01690-3 · Cited by 187
PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages
Ding, Z., Liu, S., Wang, X., Theus, S., Deng, X., Fan, Y., Zhou, S., & Mehta, J. L. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy079 · Cited by 147
Regulation of PCSK9 by nutraceuticals
Momtazi, A. A., Banach, M., Pirro, M., Katsiki, N., & Sahebkar, A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.03.023 · Cited by 131
Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages
Adorni, M. P., Cipollari, E., Favari, E., Zanotti, I., Zimetti, F., Corsini, A., Ricci, C., Bernini, F., & Ferri, N. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.11.019 · Cited by 130
Self-citationTargeting PCSK9 for hypercholesterolemia
Norata, G. D., Tibolla, G., & Catapano, A. L. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-140025 · Cited by 127
Self-citationRegulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications
Xia, X.-D., Peng, Z.-S., Gu, H.-M., Wang, M., Wang, G.-Q., & Zhang, D.-W. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.764038 · Cited by 125
Sahebkar, A., Di Giosia, P., Stamerra, C. A., Grassi, D., Pedone, C., Ferretti, G., Bacchetti, T., Ferri, C., & Giorgini, P. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12905 · Cited by 116
Exosome-based Ldlr gene therapy for familial hypercholesterolemia in a mouse model
Li, Z., Zhao, P., Zhang, Y., Wang, J., Wang, C., Liu, Y., Yang, G., & Yuan, L. (2021) · Theranostics · doi:10.7150/thno.49874 · Cited by 108
Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis
Punch, E., Klein, J., Diaba‐Nuhoho, P., Morawietz, H., & Garelnabi, M. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023328 · Cited by 101
O’Connell, E. M., & Lohoff, F. W. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00609 · Cited by 93
PCSK9 inhibition in the management of familial hypercholesterolemia
Ogura, M. (2018) · Journal of Cardiology · doi:10.1016/j.jjcc.2017.07.002 · Cited by 84
Navarese, E. P., Kołodziejczak, M., Kereiakes, D. J., Tantry, U. S., O'Connor, C., & Gurbel, P. A. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2994 · Cited by 77
PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology
Sundararaman, S. S., Döring, Y., & van der Vorst, E. P. C. (2021) · Biomedicines · doi:10.3390/biomedicines9070793 · Cited by 67
Adorni, M. P., Ruscica, M., Ferri, N., Bernini, F., & Zimetti, F. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00120 · Cited by 67
Self-citationMacchi, C., Favero, C., Ceresa, A., Vigna, L., Conti, D. M., Pesatori, A. C., Racagni, G., Corsini, A., Ferri, N., Sirtori, C. R., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01158-6 · Cited by 51
Self-citationThe role of PCSK9 in inflammation, immunity, and autoimmune diseases
Frostegård, J. (2022) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2022.2017281 · Cited by 43
Papotti, B., Adorni, M. P., Marchi, C., Zimetti, F., Ronda, N., Panighel, G., Lupo, M. G., Vilella, A., Giuliani, D., Ferri, N., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012192 · Cited by 41
Self-citationInsight into the Evolving Role of PCSK9
Maligłówka, M., Kosowski, M., Hachuła, M., Cyrnek, M., Bułdak, Ł., Basiak, M., Bołdys, A., Machnik, G., Bułdak, R. J., & Okopień, B. (2022) · Metabolites · doi:10.3390/metabo12030256 · Cited by 41
Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system
Bell, A. S., Wagner, J., Rosoff, D. B., & Lohoff, F. W. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105155 · Cited by 36
PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD)
Sobati, S., Shakouri, A., Edalati, M., Mohammadnejad, D., Parvan, R., Masoumi, J., & Abdolalizadeh, J. (2020) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2020.062 · Cited by 33
Durairaj, A., Sabates, A., Nieves, J., Moraes, B., & Baum, S. (2017) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-017-0556-0 · Cited by 27
Zulkapli, R., Muid, S. A., Wang, S. M., & Nawawi, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065098 · Cited by 27
Koskinas, K. C., Windecker, S., Buhayer, A., Gencer, B., Pedrazzini, G., Mueller, C., Cook, S., Muller, O., Matter, C. M., Räber, L., et al. (2018) · Clinical Cardiology · doi:10.1002/clc.23112 · Cited by 26
Lupo, M. G., Marchianò, S., Adorni, M. P., Zimetti, F., Ruscica, M., Greco, M. F., Corsini, A., & Ferri, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084114 · Cited by 15
Self-citationPleiotropy of PCSK9: Functions in Extrahepatic Tissues
Şener, Y. Z., & Tokgözoğlu, L. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01918-2 · Cited by 13
Mazura, A. D., & Pietrzik, C. U. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041268 · Cited by 9
Metadata
- Authors
- Ferri, N., Tibolla, G., Pirillo, A., Cipollone, F., Mezzetti, A., Pacia, S., Corsini, A., & Catapano, A. L.
- Venue
- Atherosclerosis
- Publisher
- Elsevier BV
- Published
- 2012-02
- Volume
- 220
- Issue
- 2
- Pages
- 381-386
- ISSN
- 0021-9150 (ISSN-L)
- OpenAlex
- W2160637851
- Cited by
- 258
- References
- 2
- FWCI
- 6.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
